Agile Therapeutics Announces Closing of $7.5 Million Public Offering
25 mai 2023 16h05 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 25, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the closing of its...
Agile Therapeutics Announces Pricing of $7.5 Million Public Offering
22 mai 2023 20h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 22, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) ("Agile Therapeutics" or the "Company"), a women's healthcare company, today announced the pricing of its...
Agile Therapeutics Reports First Quarter 2023 Financial Results And Provides Corporate Update
11 mai 2023 16h05 HE
|
Agile Therapeutics, Inc.
Twirla Delivers Single-Quarter Records for Retail and Non-Retail Demand; Both Channels Up 20% in First Quarter 2023 vs Fourth Quarter 2022 Total OPEX down 8% in First Quarter 2023 vs Fourth...
Agile Therapeutics to Report First Quarter 2023 Financial Results and Provide Business Update on Thursday, May 11, 2023
08 mai 2023 08h00 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., May 08, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report first quarter 2023 financial results after the...
Agile Therapeutics Announces Preliminary Expectations for First Quarter 2023
28 avr. 2023 08h01 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 28, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced preliminary expectations for first quarter 2023 Twirla®...
Agile Therapeutics Regains Compliance With Nasdaq Minimum Bid Price Requirement
26 avr. 2023 09h01 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 26, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced that it has received a notification letter from the Listing...
Agile Therapeutics Announces 1-For-50 Reverse Stock Split
10 avr. 2023 16h30 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., April 10, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile”), a women's healthcare company, today announced that its board of directors approved a 1-for-50...
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate Update
22 mars 2023 16h05 HE
|
Agile Therapeutics, Inc.
Fourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP Quarter-Over-Quarter OPEX Decreased 55% and Non-GAAP OPEX Remained Unchanged Twirla Demand and Factory Sales...
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023
21 mars 2023 09h05 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2022 financial...
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price Requirement
27 févr. 2023 08h31 HE
|
Agile Therapeutics, Inc.
PRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has received written...